Result: The rate of other drug-associated resistant mutation models, such as rtA181T+rtN236T for ADV, rtL180M+rtM204V+rtS202G for ETV, and rtL180M+rtM204V+rtT184L for ETV, did not differ between genotypes as well.
Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.
PMID: 25061278
2014
Drug design, development and therapy
Discussion: Moreover, Karatayli et al reported that HBV DNA, in seven of eight patients with ETV resistance mutations (T184F/A/L/I, S202G, and M250V), became undetectable with TDF and LAM after 6 months of treatment.
Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.
Abstract: However, this patient experienced virological breakthrough under TDF with a HBV strain bearing rtL80M, rtL180M, rtM204V/I, rtA200V, rtF221Y, rtS223A, rtT184A/L, rtR153Q, and rtV191I combined mutations without rtA194T mutation.
Abstract: Subsequently, virological breakt
Novel natural mutations in the hepatitis B virus reverse transcriptase domain associated with hepatocellular carcinoma.
Result: It is worth noting that we did not observe any of the common NA-related resistance mutations including rtM204V/I, rtS202C/G/I, rtL180M, rtA181T/V, rtT184A/I/L/G/C/M, rtA194T, rtI169T, rtV173L, rtL80I, rtN236T, and PMID: 23701433
2014
Hepatology research
Abstract: The lamivudine-resistant mutations at rtL180M and rtM204V and the entecavir-resistant mutation at rtT184L were detected in the first subject.
Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.
3Introduction: The region analyzed extends from codon rt148 to rt208 in the P ORF, which includes most RT codons corresponding to reported relevant NA-resistant aa substitutions (rtI169T, rtV173L, rtL180M, rtA181T/V, rtT184S/A/I/L/G/C/M, rtA194T, rtA202C/G/I, rt PMID: 22453135
2012
Antiviral research
Abstract: Once the entecavir and tenofovir combined therapy was started, polymerase and consequently envelope gene mutations appeared at several positions at a higher frequency than before, including the entecavir resistance-associated mutation rtT184L.